A Russian institute developing one of the country’s potential coronavirus vaccines hopes to start its final stage testing in a small section of the general public in mid-August, the institute’s director said, APA reports citing Reuters.
Globally, of 19 experimental COVID-19 vaccines in human trials, only two are in final Phase III trials - one by China’s Sinopharm and another by AstraZeneca and the University of Oxford. China’s Sinovac Biotech is set to become the third later this month.
Early results from the first small-scale human trial of the vaccine developed by the Gamaleya Institute in Moscow has shown it to be safe for use, according to the report.
“Around 14-15 August, I hope, the small amount of vaccine that we should be able to produce will enter public circulation,” Alexander Ginsburg, the institute’s director said.
This will be equivalent to a Phase III trial, since people getting the vaccine will remain under supervision.
Phase I and Phase II trials typically test the safety of a drug before it enters Phase III trials that test its efficacy on a bigger group of volunteers.